SPPI News and Press, Spectrum Pharmaceuticals Inc. From 09/06/19

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond. New clinical data from the poziotinib Phase 2 investigator-initiate...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at two upcoming conferences being held in New York on Septe...

Investment Thesis Summary Spectrum Pharmaceuticals (NASDAQ: SPPI ) has seen a round-trip of sorts in its stock price over the past three years. After surging from $5.00/share to over $20.00/share, it has since come back down to the below-$10.00/share range. The upward movement was caused b...

Last week, Elle Investments published a Top Idea on Spectrum Pharmaceuticals (SPPI). For a look behind the idea, please see their interview with the PRO+ team. Seeking Alpha: Can you briefly summarize your bullish thesis for readers who may not have seen it yet? Elle Investments: D...

Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2019 Earnings Conference Call August 8, 2019 16:30 PM ET Company Participants Shiv Kapoor - Vice President-Strategic Planning and Investor Relations Joe Turgeon - Chief Executive Officer and President Kurt Gustafson - Chief Financial Offic...

Spectrum Pharmaceuticals (NASDAQ: SPPI ): Q2 Non-GAAP EPS of -$0.23 beats by $0.13 ; GAAP EPS of -$0.26 beats by $0.10 . Cash and equivalents of $282M. Press Release More news on: Spectrum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019. “We’ve made significant progress on our pipeline in the last few m...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, August 8, 2019 at 4:30 p.m. Eastern...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) is further expanding its poziotinib clinical program by adding three new cohorts in ZENITH20 trial, evaluating the impact of poziotinib treatment on non-small cell lung cancer (NSCLC) patients. More news on: Spectrum Pharmaceuticals, Inc., Healthc...

Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR osimertinib failures), and Cohort 7 (Atypi...